Идёт набор NCT07143279

Testosterone Supplementation in Patients in Best Supportive Care: Impact on Quality of Life

Ранняя фаза I С лечением Hypotestosteronism Palliative Care

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают: В протоколе указаны: Sustanon 250.
Кому может быть актуально: Состояния в реестре: Hypotestosteronism, Palliative Care. Базовые параметры: от 18 лет · Мужчины.
Что важно проверить: Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится: Бельгия
Следующий шаг: Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Обзор

This is a monocentric, single-arm prospective pilot study that will enrol hypogonadal (testosterone \< 231 ng/dL) male subjects in best supportive care, with no further therapeutic options and no need for resuscitation. Currently, testosterone formulations for intramuscular (IM) injection and subcutaneous injection as well as for oral and transdermal administration have been approved for androgen therapy. To date, injectable testosterone is the most commonly used formulation. To increase serum testosterone levels to the physiological range IM injections of testosterone every 2-3 weeks are required, which lead to supraphysiological peaks shortly after administration, followed by a sharp fall in levels thereafter. Testosterone levels before the next injection are frequently in the hypogonadal range. For this reason, Sustanon 250® (1 ml, IM) will be administered on day 0 after confirmation of hypogonadism by blood test and then every 15 days in this trial given the limited life expectancy of the subjects and to maximise the effect and benefit of testosterone supplementation. The Edmonton questionnaire and ADL questionnaire will be completed before the injection on day 0 and then every 15 days at the time of injection until subject's death or if a subject is discontinued from the study treatment/procedures for any other reasons than death. In parallel, the EQ-5D-3L questionnaire will be completed by a family member or a proxy.

Вмешательства

Препарат Sustanon 250
Sustanon 250® (1 ml, IM) every 10 days

Первичные конечные точки

Quality of life assessed by ADL questionnaire [Срок оценки: Every 15 days through study completion]
Quality of life assessed by Edmonton Symptom Assessment Scale [Срок оценки: Every 15 days through study completion,]

Вторичные конечные точки (2)

EQ-5D-3L questionnaire [Срок оценки: Every 15 days through study completion]
Dynamic/change of the ADL and Edmonton System Assessment Scale during treatment [Срок оценки: At each time point during treatment, especially at Day 15.]

Критерии участия

Критерии включения

Male hypogonadal with total testosterone < 231 ng/dl in best supportive care with no further therapeutic options and who do not wish to be reanimated.
Age ≥ 18 years old
Patient able to understand the patient information sheet and able to sign the Informed Consent form (ICF) prior to any study related procedure.